for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CEL-SCI Corporation

CVM.A

Latest Trade

8.03USD

Change

0.24(+3.08%)

Volume

79,524

Today's Range

7.79

 - 

8.16

52 Week Range

7.11

 - 

40.91

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Latest Developments

Cel-Sci’S Multikine Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Versus 48.6%) In The Group Receiving Surgery Plus Radiotherapy

June 28 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI’S MULTIKINE® IMMUNOTHERAPY PRODUCES SIGNIFICANT 14.1% 5-YEAR SURVIVAL BENEFIT (62.7% VERSUS 48.6%) IN THE GROUP RECEIVING SURGERY PLUS RADIOTHERAPY IN A LANDMARK HEAD AND NECK CANCER PHASE 3 STUDY.CEL-SCI - DATA INDICATE SIGNIFICANT OVERALL SURVIVAL BENEFIT FOR PATIENTS WHO RECEIVED MULTIKINE TREATMENT REGIMEN FOLLOWED BY SURGERY & RADIOTHERAPY.CEL-SCI - PATIENTS TREATED WITH MULTIKINE TREATMENT REGIMEN FOLLOWED BY SURGERY AND RADIOTHERAPY DEMONSTRATED STATISTICALLY SIGNIFICANT OS ADVANTAGE.

CEL-SCI Announces Bought Deal Offering

June 8 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING.CEL-SCI CORP - UNDERWRITER HAS AGREED TO PURCHASE ON A FIRM COMMITMENT BASIS A MINIMUM OF 1 MILLION SHARES OF COMMON STOCK.

CEL-SCI Reports Q2 Loss Per Share Of $0.28

May 18 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI CORPORATION REPORTS SECOND QUARTER FISCAL 2021 FINANCIAL RESULTS.CEL-SCI CORP - QTRLY LOSS PER SHARE $0.28.

CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results

Feb 16 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI CORPORATION REPORTS FIRST QUARTER FISCAL 2021 FINANCIAL RESULTS.CEL-SCI CORP - QTRLY LOSS PER SHARE $0.21.

Cel-Sci Says Financial Statements Within Quarterly Reports For Quarter Ended Dec 31, 2019, March 31, 2020, & June 30, 2020 Should Not Be Relied Upon

Dec 29 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI - FINANCIAL STATEMENTS WITHIN QUARTERLY REPORTS FOR QUARTER ENDED DEC 31, 2019, MARCH 31, 2020, & JUNE 30, 2020 SHOULD NOT BE RELIED UPON.CEL-SCI - DETERMINED THAT OPENING FINANCE ROU ASSET AND STOCKHOLDERS' EQUITY BALANCES WERE UNDERSTATED BY ABOUT $2.04 MILLION AS OF OCTOBER 1, 2019.CEL-SCI CORP - EXPECTS TO FILE AMENDED QUARTERLY REPORTS AS SOON AS POSSIBLE.

CEL-SCI Posts Qtrly Loss Per Share $0.68

Aug 11 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI CORPORATION REPORTS THIRD QUARTER FISCAL 2020 FINANCIAL RESULTS.CEL-SCI CORP QTRLY LOSS PER SHARE $0.68.

Cel-Sci Corporation Reports Qtrly Loss Per Share Of $0.27

Aug 11 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI CORP QTRLY LOSS PER SHARE $0.27 .CEL-SCI CORPORATION REPORTS THIRD QUARTER FISCAL 2020 FINANCIAL RESULTS.

Cel-Sci Corp Reports Q2 Loss Per Share Of $0.25

May 11 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI CORPORATION REPORTS SECOND QUARTER FISCAL 2020 FINANCIAL RESULTS.CEL-SCI CORP - QTRLY LOSS PER SHARE $0.25.

Cel-Sci Announces Bought Deal Offering

March 23 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING.CEL-SCI - UNDERWRITING AGREEMENT WITH AEGIS CAPITAL; UNDERWRITER AGREED TO PURCHASE MINIMUM OF 500,000 SHARES OF CO'S COMMON STOCK AT $12.22/ SHARE.

CEL-SCI Corp Reports Q1 Loss Per Share Of $0.16

Feb 10 (Reuters) - CEL-SCI Corp <CVM.A>::CEL-SCI CORPORATION REPORTS FIRST QUARTER FISCAL 2020 FINANCIAL RESULTS.CEL-SCI CORP QUARTERLY LOSS PER SHARE $0.16.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up